Optimizing Treatments for Heart Failure During Hospitalization (OPTICARD)

February 11, 2026 updated by: Pr. Nicolas GIRERD, Central Hospital, Nancy, France

Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year.

Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2).

Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality.

The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

184

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Ars-Laquenexy, France, 57530
        • CHR Metz Thionville
      • Vandœuvre-lès-Nancy, France, 54500
        • CHRU de Nancy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Hospitalized (≥24h) patient for decompensated heart failure in cardiology between november 2021 and october 2022

Description

Inclusion Criteria:

  • Patient ≥ 18 years
  • Hospitalized (≥24h) for decompensated heart failure in cardiology.

Exclusion Criteria:

  • Patient opposition participation in research and use of data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prescription score
Time Frame: During hospitalisation for decompensated heart failure (up to 10 days)
Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2.
During hospitalisation for decompensated heart failure (up to 10 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
serum concentration of creatinine
Time Frame: During hospitalisation for decompensated heart failure (up to10 days)
Creatinine measured at admission and discharge
During hospitalisation for decompensated heart failure (up to10 days)
serum concentration of potassium
Time Frame: During hospitalisation for decompensated heart failure (up to 10 days)
Potassium measured at admission and discharge
During hospitalisation for decompensated heart failure (up to 10 days)
Concentration of hemoglobin
Time Frame: During hospitalisation for decompensated heart failure (up to 10 days)
hemoglobin measured at admission and discharge
During hospitalisation for decompensated heart failure (up to 10 days)
All cause Death
Time Frame: 6 months
6 months
Rate of hospitalization for heart failure
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Investigators

  • Study Chair: Nicolas GIRERD, MD-PhD, CHRU de Nancy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 8, 2023

Primary Completion (Actual)

November 29, 2023

Study Completion (Actual)

November 29, 2023

Study Registration Dates

First Submitted

April 28, 2023

First Submitted That Met QC Criteria

June 15, 2023

First Posted (Actual)

June 18, 2023

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 11, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022PI115

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Decompensated Heart Failure

Clinical Trials on Hospitalized patient for decompensated heart failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe